AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17929300
Drug: On treatment
RxNorm normalized name: STIX 3 DAY YEAST INFECTION TREATMENT KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On treatment (RRs and SRs)
Trial: 10770145
Drug: Sertraline hydrochloride
RxNorm normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline hydrochloride (50 to 200 mg/d, starting at 25 mg/d)
Trial: 8420682
Drug: Three monthly
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three monthly cycles of cyclophosphamide and cisplatin
Trial: 3552699
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 3 g cephalexin
Trial: 3552699
Drug: 3 days
RxNorm normalized name: Transderm Scop 1mg/3 days Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days of cephalexin 1 g or combined preparation of pivmecillinam-pivampicillin
Trial: 2566825
Drug: rIFN-gamma treatment
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN-gamma treatment for lesions due to Leishmania braziliensis guyanensis
Trial: 2566825
Drug: rIFN-gamma treatment
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN-gamma treatment for lesions due to Leishmania tropica
Trial: 2566825
Drug: rIFN-gamma treatment
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN-gamma treatment
Trial: 31984406
Drug: Micro total
RxNorm normalized name: Lipantil Micro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro total analysis system (μTAS) based on electrochemical measurements and dielectrophoretic sorting for screening of NAD(P)‐dependent oxidoreductases; specific details on dosage and duration not available.
Trial: 31984406
Drug: Boron-doped diamond
RxNorm normalized name: diamond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boron-doped diamond (BDD) electrode for high-throughput measurement of enzyme activity; specific details on dosage and duration not available.
Trial: 28852842
Drug: Combined nutraceutical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined nutraceutical supplement (one daily tablet containing phytoestrogens, vitamins, micronutrients, and passion flower herbal medicine) for 6 months
Trial: 28852842
Drug: Combined nutraceutical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined nutraceutical supplement
Trial: 25274038
Drug: PSA screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA screening every 4 years (cut-off 4 ng/ml)
Trial: 24144057
Drug: Glycine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine (15 g/day)
Trial: 21338741
Drug: Large portion
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large portion size (300 g)
Trial: 21338741
Drug: Small portion
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small portion size (150 g)
Trial: 19687576
Drug: Interferon-beta monotherapy
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-beta monotherapy for < or = 24 weeks
Trial: 17005085
Drug: Kaixin Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaixin Capsule (KXC) in combination with conventional Western medicine
Trial: 17005085
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western medicine (Control)
Trial: 15546056
Drug: Acute day
RxNorm normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute day hospital treatment (87.7 days)
Trial: 15546056
Drug: Conventional inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional inpatient treatment (67.8 days)
Trial: 8447244
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dose lithium
Trial: 8447244
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily dose lithium
Trial: 3533265
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 mg daily for five weeks)
Trial: 3533265
Drug: Clonidine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.25 mg daily for five weeks)
Trial: 30567725
Drug: 20 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 of IV decitabine on days 1 to 10 for up to 4 10-day cycles followed by monthly 5-day cycles
Trial: 27311915
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (KE)
Trial: 27311915
Drug: Conventional anaesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional anaesthetics (high dose midazolam, thiopental and/or propofol)
Trial: 25855109
Drug: Home self
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home self administration of vaginal misoprostol (800 mcg)
Trial: 25855109
Drug: Hospital administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital administration of vaginal misoprostol (800 mcg)
Trial: 25855109
Drug: Home self
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home self administration of vaginal misoprostol (800 mcg) after 2nd dose (400 mcg)
Trial: 25855109
Drug: Hospital administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital administration of vaginal misoprostol (800 mcg) after 2nd dose (400 mcg)
Trial: 25855109
Drug: Home self
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home self administration of vaginal misoprostol
Trial: 25855109
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of extra dose of misoprostol
Trial: 8368548
Drug: Fast injection
RxNorm normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fast injection (FI) of isobaric 0.5% bupivacaine (2 mL during 2 to 3 s or approximately 0.75 mL/s)
Trial: 8368548
Drug: Slow injection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow injection (SI) of isobaric 0.5% bupivacaine (1 mL/min)
Trial: 8368548
Drug: Fast reinjection
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast reinjection (FI group) of isobaric 0.5% bupivacaine (10 mg, 2 mL)
Trial: 8368548
Drug: Slow reinjection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow reinjection (SI group) of isobaric 0.5% bupivacaine (10 mg, 2 mL)
Trial: 31856840
Drug: Neoadjuvant concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by esophagectomy with a long interval (8-12 weeks)
Trial: 31856840
Drug: Neoadjuvant concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by esophagectomy with a short interval (4-7 weeks)
Trial: 26961539
Drug: LCZ696 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 50 mg
Trial: 20236700
Drug: LCZ696 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 200 mg
Trial: 26961539
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of LCZ696
Trial: 25314578
Drug: Whole-body cryostimulation
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body cryostimulation (WBC) daily during intensified training (ITWBC)
Trial: 21667042
Drug: GS-9450 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9450 (10 mg)
Trial: 10843174
Drug: Continued GH
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued GH therapy (0.018 +/- 0.001 mg/kg day)
Trial: 10843174
Drug: Open phase
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open phase GH therapy (0.016 mg/kg x day)
Trial: 10843174
Drug: Continued GH
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued GH treatment
Trial: 6686808
Drug: Liquid antacids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid antacids (various doses)
Trial: 6686808
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with anticholinergic and antacids
Trial: 6686808
Drug: Antacids (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids (high dose)
Trial: 25477278
Drug: 3D documentation
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D documentation system using Tumor Therapy Manager (TTM)
Trial: 24406481
Drug: Sibutramine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine treatment (6-week period)
Trial: 24406481
Drug: Long-term sibutramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-term sibutramine treatment
Trial: 17131132
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (Sucralfate and Mucaine)
Trial: 8739659
Drug: Pharmacotherapy (specifics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (specifics not detailed, but includes alprazolam for a subgroup of 26 patients)
Trial: 2183864
Drug: Extradural pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extradural pethidine 50 mg
Trial: 2183864
Drug: i.m. pethidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. pethidine 100 mg
Trial: 26295650
Drug: Low-dose (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose (260 mAs)
Trial: 24586897
Drug: Treatment Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Plus Automated Emails Group (TEG)
Trial: 24586897
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment Group (TG)
Trial: 24586897
Drug: Delayed-Treatment Waitlist
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-Treatment Waitlist Control Group (Control)
Trial: 20231532
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (5 mg folic acid, 50 microg vitamin B(12), 20 mg vitamin B(6))
Trial: 20231532
Drug: Placebo (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.2 mg folic acid, 4 microg vitamin B(12), 1.0 mg vitamin B(6))
Trial: 17430744
Drug: Natural laxative
RxNorm normalized name: Natural Laxative
DrugBank: Sennosides (DB11365)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Natural laxative mixture (Beverley-Travis), 2 tablespoons twice a day for 4 weeks
Trial: 17430744
Drug: Prescribed laxatives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed laxatives (control group)
Trial: 17430744
Drug: Natural laxative
RxNorm normalized name: Natural Laxative
DrugBank: Sennosides (DB11365)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Natural laxative mixture
Trial: 11932294
Drug: T enanthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T enanthate (TE) 250 mg/wk im plus ethinylestradiol (EE2) 0.1 mg/d orally for 5.8 weeks
Trial: 7612363
Drug: Intravenous ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ranitidine 50 mg initially, followed by 50 mg every 6 hours
Trial: 7612363
Drug: Intravenous omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous omeprazole 80 mg bolus initially, followed by 40 mg every 8 hours for 48 hours, then 40 mg every 12 hours until discharge
Trial: 2371367
Drug: Sodium amytal
RxNorm normalized name: amobarbital sodium Injection [Amytal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium amytal (250 mg)
Trial: 889069
Drug: Naloxone (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (high doses)
Trial: 10963811
Drug: Birch-pollen immunotherapy
RxNorm normalized name: cherry birch pollen extract
DrugBank: Betula lenta pollen (DB10352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birch-pollen immunotherapy (IT)
Trial: 11776511
Drug: Hysteroscopic tubal
RxNorm normalized name: sodium thiosalicylate Injectable Solution [Tusal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hysteroscopic tubal embryo transfer (h-TEST) using a catheter tapering at the distal 3 cm
Trial: 11776511
Drug: Hysteroscopic tubal
RxNorm normalized name: sodium thiosalicylate Injectable Solution [Tusal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hysteroscopic tubal embryo transfer (h-TEST) using a catheter tapering at the distal 5 cm
Trial: 9128316
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg taken late in the evening, coupled with clarithromycin 250 mg b.i.d. and metronidazole 500 mg b.i.d. for the first 2 weeks.
Trial: 9128316
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg taken before breakfast, coupled with clarithromycin 250 mg b.i.d. and metronidazole 500 mg b.i.d. for the first 2 weeks.
Trial: 1088951
Drug: Haloperidol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (1.0 mg, intramuscular injection)
Trial: 21464195
Drug: 2009 pandemic
RxNorm normalized name: Influenza A virus H1 2009 pandemic Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine (Focetria) administered in 2 doses (dose 1 at enrollment and dose 2 after 4 weeks)
Trial: 21464195
Drug: 2009 pandemic
RxNorm normalized name: Influenza A virus H1 2009 pandemic Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine (Focetria)
Trial: 19542766
Drug: Long-term intake
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term intake of 'benifuuki' green tea (34 mg O-methylated catechin per day for 1.5 months before pollen exposure)
Trial: 16731323
Drug: Tramadol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (20 mg bolus, n = 13)
Trial: 9656405
Drug: Ofloxacin containing
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin containing combined drug regimens
Trial: 3168500
Drug: Oral nonabsorbable
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nonabsorbable antimicrobial agents (tobramycin, amphotericin B, polymyxin E) in addition to parenteral antibiotics
Trial: 3168500
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no nonabsorbable antimicrobial agents)
Trial: 3168500
Drug: Oral nonabsorbable
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nonabsorbable antimicrobial agents
Trial: 21592480
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/day for 4 weeks
Trial: 14582689
Drug: Monochromatic pulsating
RxNorm normalized name: ABG Pulsator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monochromatic pulsating light treatment
Trial: 11078237
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg plus Fenofibrate 200 mg
Trial: 11078237
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg plus Fenofibrate 200 mg
Trial: 29381726
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (NVM group)
Trial: 26771282
Drug: Food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplement containing forskolin, homotaurine, carnosine, folic acid, vitamins B1, B2, B6, and magnesium, 2 tablets per day for 12 months.
Trial: 26771282
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (not specified in detail).
Trial: 24631567
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tDCS and MP
Trial: 22271411
Drug: Colesevelam 1.875
RxNorm normalized name: colesevelam 1.875 g oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam 1.875 g b.i.d. for 14 days
Trial: 20306005
Drug: Intensive vascular
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive vascular care (4-monthly visits to a practice nurse monitoring cardiovascular risk factors)
Trial: 18925641
Drug: Combination HBIG
RxNorm normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination HBIG plus lamivudine
Trial: 18925641
Drug: Combination adefovir/lamivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination adefovir/lamivudine prophylaxis
Trial: 11863090
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus carboplatin (PC) - P 175 mg/m2 and C at AUC = 7, intravenous infusion on day 1
Trial: 11863090
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus gemcitabine (PG) - P 175 mg/m2 on day 1 and G 1000 mg/m2 on days 1 and 8, every 3 weeks
Trial: 7572513
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml gadopentetate dimeglumine
Trial: 7572513
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml gadopentetate dimeglumine
Trial: 7572513
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml gadopentetate dimeglumine
Trial: 7011019
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily applications of a povidone-iodine solution and ointment
Trial: 7011019
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily meatal cleansing with a nonantiseptic solution of green soap and water
Trial: 7011019
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment) for povidone-iodine
Trial: 31079535
Drug: Pegloticase (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegloticase (8 mg every 2 weeks)
Trial: 28962046
Drug: Sodium butyrate
RxNorm normalized name: Sodium butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium butyrate capsules
Trial: 28962046
Drug: Inulin supplement
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inulin supplement powder
Trial: 19683825
Drug: Bed-time NPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bed-time NPH insulin
Trial: 15281501
Drug: Bupivacaine (0.125%;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.125%; 0.2 mg x kg(‐1) x h(‐1))
Trial: 15281501
Drug: Levobupivacaine (0.125%;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine (0.125%; 0.2 mg x kg(‐1) x h(‐1))
Trial: 15281501
Drug: Ropivacaine (0.125%;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (0.125%; 0.2 mg x kg(‐1) x h(‐1))
Trial: 9990415
Drug: Tretinoin formulations
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin formulations (0.05% and 0.1%)
Trial: 9990415
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% gel and cream
Trial: 3415207
Drug: Moxalactam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam (2 g i.v. every 8 h for 5 doses, then 2 g every 12 h)
Trial: 3415207
Drug: Clindamycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (600 mg i.v. every 6 h) plus Gentamicin (1.5 mg/kg i.v. every 8 h)
Trial: 27703346
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid (ICS)
Trial: 25215556
Drug: Placebo infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusions (Z3P3, n = 617)
Trial: 25215556
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of treatment after 3 years
Trial: 18154091
Drug: 5-fluorouracil administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil administration during skin plasty operation